In a previous study the small molecule SJP-L-5 that inhibits HIV replication, has been shown to block uncoating of the viral capsid. Continued study showed that SJP-L-5 might hinder HIV capsid uncoating by blocking the completion of reverse transcription. However, to date, the mechanism has not been fully elucidated. Here, the effects of SJP-L-5 for reverse transcription were explored via quantitative PCR, DIG-labelled ELISA, fluorescent resonance energy transfer, and Southern blot assays. We also analyzed the resistance profile of this compound against reverse transcriptase. Our results show that SJP-L-5 preferentially inhibits PPT primed plus-strand DNA synthesis (EC50 = 13.4 ± 3.0 μM) over RNA primed minus-strand DNA synthesis (EC50 > 3,646 μM), resulting in formation of five segmented plus-strand DNA and loss of HIV DNA flap, suggesting failure of both nuclear import and integration. Moreover, resistance study evidenced that SJP-L-5 requires the amino acid residues Val108 and Tyr181 to exert an inhibitory effect. These results indicate SJP-L-5 as a new non-nucleoside reverse transcriptase inhibitor that inhibits HIV-1 polypurine tract primed plus-strand DNA synthesis, initiating HIV-1 down-stream plus-strand DNA synthesis at multiple sites under drug pressure.
Retroviruses (i.e., human immunodeficiency virus, HIV) are single-stranded RNA viruses that infect eukaryotic cells. The retroviral life cycle is characterized by reverse transcription (RT) of the single-stranded plus RNA genome and integration of the complementary DNA (cDNA) into the host genome. RT is a key step in HIV replication, and this process is responsible for the synthesis of a double-strand DNA from the viral single-strand RNA genome1.
RT is a complex process in which reverse transcriptase (RTase) has three functions and makes two jumps2. These three RTase functions include: (1) RNA-dependent DNA polymerization (RDDP) activity, converting single-stranded viral RNA to minus DNA; (2) DNA-dependent DNA polymerization (DDDP) activity, converting minus DNA to plus DNA; (3) RNase H activity, digesting RNA from RNA/DNA hybrids3. The first RTase jump is triggered by a minus-strand strong-stop DNA (−sssDNA), which is used as a primer to synthesize a large minus-DNA fragment. The second jump is triggered by the plus-strand strong-stop DNA (+sssDNA) near the 3′ end of the RNA genome, synthesized from the 3′ polypurine tract (PPT), which is used as a primer. After these two jumps, three types of viral DNA have been synthesized: linear DNA, long-terminal repeat (LTR) DNA, and 2-LTR DNA (Fig. 1). Unlike other retroviruses (i.e., MMV or AMV), HIV, as a lentivirus, has a PPT sequence in the center of the RNA genome (central PPT or cPPT), as well as in the integrase gene4. Previous studies suggested that the cPPT forms a gap called flap in the center of the linear DNA during RT. Thus, plus DNA of the HIV genome is discrete and holds a triple DNA structure in the center that is essential for importing the pre-integrated complex into the nucleus5. Hence, this DNA flap is a potential target of anti-HIV drugs; however, such inhibitors are rarely reported. A DNA flap inhibitor could also help understanding the late process of reverse transcription, as well as the early steps of nuclear import.
Since the first RTase inhibitor, zidovudine (AZT), was approved by the FDA three decades ago, RTase has become a major target in highly active antiretroviral therapy (HAART) against HIV infection6. Unlike nucleoside RTase inhibitors (NRTIs), non-nucleoside RTase inhibitors (NNRTIs) bind to the hydrophobic bag and inhibit its polymerase activity by an allosteric effect. Normally, NNRTIs inhibit both RNA- and DNA-dependent DNA polymerization activities, but not the ribonuclease H (RNase H) activity.
Our previous study showed that SJP-L-5 (Fig. 2), a nitrogen-containing biphenyl compound, whose synthesis was based on dibenzocyclooctadienelignan, gomisin M2 (SM-10), blocks the nuclear entry of the HIV pre-integrated complex by inhibiting capsid uncoating7. However, the mechanism with which SJP-L-5 blocks the uncoating of the viral capsid remains unknown. Our data (unpublished) suggested that SJP-L-5 may inhibit the RTase DNA-dependent DNA polymerase function. Therefore, we hypothesize that SJP-L-5 inhibits the viral plus-strand DNA synthesis by hindering full-length plus-strand DNA maturation.
Taking our hypothesis into account, we examined the molecular mechanisms of SJP-L-5 inhibition. Here, we present new data on SJP-L-5 and its inhibitory activity on the three RTase functions. We also analyze the effect of SJP-L-5 on the synthesis of viral plus- and minus-strand DNA. Finally, we show a viral resistance profile of SJP-L-5 against HIV-1IIIB.
SJP-L-5 does not block the initiation of reverse transcription, but partially decreases late-RT products in HIV-1IIIB-infected C8166 cells
In our previous study, we showed that the antiviral target of SJP-L-5 is the uncoating of the capsid, based on single-round pseudotyped virus investigation7. Completion of RT is believed to trigger capsid disassembling8. To explore the stage at which this compound inhibits multi-round replicative viruses, real-time qPCR assays were carried out. The -sssDNA is a signal of RT initiation, which involves RTase RDDP activity. On the other hand, late-RT DNA is a signal of late RT, which involves the RTase DDDP activity. Dead-end circular 2-LTR DNA is a nuclear import signal.
In the first 4 h, -sssDNA levels were not reduced by SJP-L-5, at a concentration sufficient to block the HIV-1 infection in cell-based assays (100 μM) (Fig. 3a). However, late-RT DNA products were partially reduced by this compound from 4 to 8 h (Fig. 3b), and 2-LTR levels were totally inhibited by SJP-L-5 from 8 to 12 h (Fig. 3c). The positive control (EFV) reduced the levels of the three viral DNA forms, suggesting that it inhibits the early steps of RT. Taken together, these results show that SJP-L-5 blocks HIV-1 infection during the late process of RT.
SJP-L-5 inhibits DDDP activity in a dose-dependent response
Based on the data shown in Fig. 3, we predicted that SJP-L-5 would target the DDDP. To evaluate this assumption, we measured the three functions of the RTase. We conducted a DIG-labelled dUTP ELISA to evaluate the RDDP activity, and a fluorescent-labelled dUTP assay to detect the DDDP or the RNase H activities.
As shown in Fig. 4a, the RTase RDDP activity was barely inhibited at the highest concentration of SJP-L-5 (inhibitory rate <25% at 3,646 μM) but was efficiently blocked by NVP with an EC50 of 3.98 ± 2.26 μM in a dose-dependent manner, suggesting that the RDDP activity is not the main target of SJP-L-5. However, the DDDP activity was inhibited by both SJP-L-5 and NVP in a dose-dependent manner, displaying an EC50 of 13.4 ± 3.0 μM and 342 ± 35 nM, respectively (Fig. 4b). This result shows that SJP-L-5 is an inhibitor of the RTase DDDP activity and, thus, may interfere with viral plus-DNA synthesis. Neither SJP-L-5 nor NVP inhibited the RNase H activity (Fig. 4c).
SJP-L-5 accumulates different-length viral downstream plus-strand DNA delaying viral DNA maturation
Next, we assessed the impact of SJP-L-5 on viral plus-strand DNA synthesis and DDDP activity by treating the cells with this inhibitor. DNA flap is a viral plus-strand DNA that is discrete when the RT just finished9,10. Based on this feature, Southern blot analysis in denaturing conditions was carried out. Two different probes were used, namely, a double-stranded DNA probe within the RTase gene next to the genomic 5′ end and a downstream plus-strand DNA probe within the gp41 gene next to the genomic 3′ end.
The upstream half-genome of the plus- and minus-strand DNA was detected with a double-stranded DNA probe in SJP-L-5- or NVP-treated cells. Both plus- and minus-strand DNA levels remained unaltered at increasing concentrations of SJP-L-5 (Fig. 5c). Moreover, upstream plus-strand DNA was higher than the control, suggesting that SJP-L-5 would not block upstream plus-strand DNA synthesis. On the other hand, plus- and minus-strand DNA levels decreased with NVP in a dose-dependent manner, suggesting that NVP inhibits both types of DNA (plus and minus). Downstream plus-strand DNA levels, detected with a plus-strand DNA probe, accumulated with SJP-L-5 in a dose-dependent manner (Fig. 5c), exhibiting at least five different DNA lengths (Fig. 5b), suggesting that SJP-L-5 induces multiple initiation sites to start the downstream plus-strand DNA synthesis while usually only the cPPT site is used as a primer. These results demonstrate that SJP-L-5 delays viral downstream plus-strand DNA maturation, disturbing formation of a triple-DNA flap.
SJP-L-5 induces mutation of the RTase gene in genotypic resistance assays
To further investigate the characteristics of SJP-L-5 inhibition of the RTase, we selected resistant viruses from HIV-1IIIB-infected C8166 cells exposed to increasing concentrations of SJP-L-5, and sequenced the RTase gene for a genotypic assay. Since it is very difficult to introduce a mutation in a live virus, we used the plasmid pNL4-3 (the RTase DNA sequence of IIIB and NL4-3 are highly similar with a similarity >99%) as a tool to perform site-directed mutations.
SJP-L-5 concentrations were increased from 0.9 to 122 μM during 11 passages to select resistant HIV-1IIIB viruses (Fig. 6a). After a 96-day selection, an SJP-L-5 resistant strain was obtained: HIV-1L-5resi. The EC50 of SJP-L-5 against HIV-1L-5resi was above 608 μM (1240-fold higher than the wild-type, Fig. 6b) and higher than the 122 μM value obtained in the virus selection assay, suggesting we successfully obtained a SJP-L-5-resistant virus strain. Afterwards, the DNA of HIV-1L-5resi-infected C8166 cells was extracted and the full-length RTase sequence (1680 bp) was analyzed. The sequence analysis revealed that seven amino acids were mutated within the RTase gene, namely, V108I, E138K, Y181C, and L214F within the DNA polymerase motif, and N447S, R461K, and A508T within the RNase H motif (Fig. 6c). These results show that SJP-L-5 induces gene mutations and supports the idea which the RTase is a target of this inhibitor.
SJP-L-5 exhibits diminished activity against NNRTIs resistant mutants, but is sensitive to NRTIs resistant mutants in phenotypic resistance assays
To understand the interactions between the RTase and SJP-L-5, we investigated whether SJP-L-5 would be less sensitive to RTase mutants. Three single-site mutants (V108I, E138K, and Y181C, located in the polymerase domain), which were indicated from genotypic resistance assays, were used for a phenotypic resistance assay with SJP-L-5. Additionally, other known resistant viruses (HIV-1A17, HIV-174V, and HIV-1A018) were tested. As shown in Table 1, SJP-L-5 was resistant to NNRTI mutations, including V108I, E138K, Y181C, and “K103N + Y181C”, with fold changes (FC) ranging from 25 to 158. However, SJP-L-5 was sensitive to NRTI mutations (HIV-1L74V and HIV-1AO18, with FC of 0.8 and 1.4, respectively). NVP displayed similar antiviral characteristics to SJP-L-5 against mutants and resistant viruses. In summary, our results suggest that SJP-L-5 is an NNRTI. However, it exerts a novel mechanism as SJP-L-5 preferentially inhibits the RTase DDDP activity instead of the RDDP.
To date, there are five NNRTIs in clinical use, including nevirapine, delavirdine, efavirenz, etravirine, and rilpivirine. These drugs inhibit viral minus-strand DNA synthesis11,12,13,14,15. Here, we describe a novel compound, SJP-L-5, which inhibits the plus-strand DNA elongation rather than minus-strand DNA synthesis, presenting a different mechanism from that utilized by marketed drugs.
The synthesis of the minus-strand DNA is initiated by a tRNA primer, which binds to the primer-binding site (PBS) near the 5′ end of the viral genomic RNA. Initiation of RT is conducted by RTase RDDP activity from the tRNA primer, and the synthesis of -sssDNA is one of the first products of this process16. Real-time qPCR assays showed that SJP-L-5 does not reduce the -sssDNA products in the first 4 h, but reduces late-RT and 2-LTR DNA levels (Fig. 3a–c). These results demonstrate that SJP-L-5 blocks HIV-1 infection through RT inhibition, although it does not work early in this process. This mechanism is quite different from those previously reported since all FDA-approved NNRTIs target the RDDP activity while SJP-L-5 inhibits the DDDP activity6,17.
Recently, the emergence of drug resistance has become a major concern in antiviral therapy1,18,19. To overcome this issue, on one hand, a series of novel structural compounds were designed, such as rilpivirine and dolutegravir15,20; on the other hand, new drug targets are gaining more attention, for example, RNase H of RTase21,22. To understand the mechanisms with which SJP-L-5 blocks RTase, we analyzed the three functions of the viral enzyme with methods that include ELISA and FRET. SJP-L-5 inhibited the RTase DDDP activity in a dose-dependent manner with an EC50 of 13.4 ± 3.0 μM. Strikingly, this compound showed little inhibition of the RDDP activity, which is distinctive from other NNRTIs. RNase H inhibition was not observed either (Fig. 4c). Cell-based qPCR assays suggested that SJP-L-5 preferentially inhibits plus-strand DNA synthesis rather than minus-strand DNA formation. These interesting results prompted the question of the mechanism of this inhibition. We next focused on the HIV DNA flap, a special DNA structure that exists in lentiviruses and is formed by discontinuous plus-strand DNA synthesis.
Two decades ago, it was reported that HIV reverse-transcribed DNA is discontinuous and bears two initiation sites to synthesize the viral plus-strand DNA4,9,10. Later, researchers found that a triple-DNA structure formed by the discontinuous plus-strand, called DNA flap, contributes to the nuclear import of the HIV-1 genome5. DNA flap was then believed as a viral promoting element for the uncoating of HIV-1 at the nuclear pore23. In recent years, RT and uncoating seem to be sequential processes since RT influences uncoating kinetics. DNA-RNA hybrid molecules may form a more rigid extended structure, which in turn could provide the outward force to destabilize the capsid during the early steps of RT8. Our published data demonstrated that SJP-L-5 blocks viral DNA nuclear entry by interrupting capsid disassembling7. In this paper, we analyzed the late process of RT by Southern blot. DNA hybridization data showed that SJP-L-5 does not inhibit the minus-strand DNA formation but impairs downstream plus-strand DNA elongation (Fig. 5). These results suggest that SJP-L-5 is a special RTase inhibitor that blocks the central DNA flap to be linearized by retaining the viral downstream plus-strand DNA at half genomic length. In answer to our previous question, we described the viral capsid uncoating delay in the SJP-L-5 treatment group. Due to the novel mechanism underlying SJP-L-5 inhibition, it was not possible to discover its role in our previous study7. From our experience, we strongly suggest that the three functions of the RTase are evaluated during antiviral drug screening.
NNRTIs are small hydrophobic molecules that inhibit the HIV-1 RTase by an allosteric effect. They bind to a pocket located about 10 Å away from the dNTP binding site24. We used resistance assays, including resistance selection and mutant sensitivity assays, to explore the interactions between SJP-L-5 and HIV-1 RTase. Since this compound did not inhibit RNaseH, we did not further evaluate the RNaseH mutations (N447S, R461K, and A508T) with SJP-L-5. Moreover, L214F occurs naturally as a polymorphism and does not cause NNRTI resistance25. The results showed that SJP-L-5 is resistant to V108I, E138K, Y181C, and “K103N + Y181C”, which are traditional resistance sites of NNRTIs26; the main sites being V108I and Y181C, based on genotypic and phenotypic assays. These results suggest that SJP-L-5 may bind to Val108 and Tyr181 more firmly than to other amino acids. Therefore, SJP-L-5 binds to the HIV-1 RTase hydrophobic bag in the same way as NNRTIs. However, our study shows that SJP-L-5 preferentially inhibits RTase DDDP activity. RT needs to be further investigated and, to this regard, SJP-L-5 could be a valuable tool to understand this process.
Multiple segmented plus-strand DNA is rarely reported in HIV but was observed in another retrovirus: the avian sarcoma-leukosis virus (ASLV), which is an alpharetrovirus genus virus27. Previous studies showed that only one gap (a triple DNA flap) exists in the center of HIV DNA genome4,5,9. Our results suggest that more than one gap may exist under the treatment of SJP-L-5. This phenomenon provides insight into the details of HIV reverse transcription. However, why segmented plus-strand DNA only formed under the pressure of SJP-L-5 needs to be further investigated.
Based on our results, we suggest a model of how SJP-L-5 inhibits HIV-1 replication (Fig. 7). Typically, the HIV-1 DNA genome is formed during reverse transcription with a triple-DNA flap at the center. This flap has been suggested as a cis-determinant of nuclear import5. Under SJP-L-5 treatment, both cPPT and PPT primed DNA dependent DNA synthesis are inhibited. Furthermore, HIV-1 uses multiple sites to initiate DNA replication in the downstream plus-DNA, leading to five lengths of DNA, one cPPT gap, and formation of one PPT gap. Without flap formation, the defective viral genome cannot enter the host cell nucleus, and virus replication is blocked.
In conclusion, SJP-L-5 inhibits the late stage of the RT process and preferentially inhibits plus-strand DNA synthesis over minus-strand DNA, resulting in formation of five segmented plus-strand DNA fragments and deficient HIV DNA flap, suggesting that both nuclear import and integration failed. Moreover, the resistance study evidenced that SJP-L-5 requires the amino acid residues Val108 and Tyr181 to exert its inhibitory effect. These results indicate SJP-L-5 as a new NNRTI that inhibits HIV-1 polypurine tract (PPT) primed plus-strand DNA synthesis, while initiating HIV-1 down-stream plus-strand DNA synthesis at multiple sites under drug pressure.
Materials and Methods
Compounds and reagents
SJP-L-5, with a molecular weight of 329.13, was provided by Professor Handong Sun (Kunming Institute of Botany, Chinese Academy of Sciences). Nevirapine (NVP) and efavirenz (EFV) were purchased from US Pharmacopeia (USA). All compounds were dissolved in dimethyl sulfoxide (DMSO) and stored at −20 °C. DMSO, Tris, KCl, MgCl2, 3-[(3-cholamidopropyl) dimethylammonio]−1-propane sulfonate (CHAPS), dithiothreitol (DTT), and ethylene glycol tetra-acetic acid (EGTA) were purchased from Sigma-Aldrich (USA). dUTP-AF555 was purchased from Invitrogen (USA), and dATP, dCTP, and dGTP were purchased from Takara (China).
Cells and viruses
C8166 cells were kindly provided by the AIDS Reagent Project, the UK Medical Research Council (MRC). C8166 are human T-lymphoblastoid cells sensitive to HIV infection, exhibiting a rapid and pronounced cytopathic effect. C8166 cells were cultured in RPMI 1640 medium supplemented with 10% (v/v) fetal bovine serum (FBS) with 100 U/mL penicillin G and 100 μg/mL streptomycin in a humidified incubator with 5% CO2 at 37 °C. Laboratory-adapted strains (HIV-1NL4-3) and RT-inhibitors resistant strains (HIV-1A17, HIV-174V, and HIV-1A018) were obtained from the NIH AIDS Research and Reference Reagent Program (Bethesda, MD, USA). All viruses were propagated in C8166 cells.
Quantitative PCR of viral reverse transcripts
C8166 cells were seeded at a density of 1 × 106 cells/well in 24-well culture plates and infected with HIV-1IIIB at M.O.I. 0.5 for 2 h under gentle rocking every 15 min at 4 °C. After 2 h of virus adsorption, the cells were washed and synchronized. Then, the cells were incubated in presence or absence of 100 μM SJP-L-5, 200 nM EFV, or 0.5% (v/v) DMSO. Cells were collected at 0, 1, 2, 4, 6, 8, 12, and 24 h of incubation with the drugs. Total cellular DNA was isolated using Blood Gen Mini Kit (CWBIO, China). The -sssDNA was amplified using hRU5-F2 (5′-GCC TCA ATA AAG CTT GCC TTG A-3′) and hRU5-R (5′-TGA CTA AAA GGG TCT GAG GGA TCT-3′) primers with the hRU5-P probe (5′-FAM-AGA GTC ACA CAA CAG ACG GGC ACA CAC TA-TAMRA-3′). Late reverse transcription product U5ψ (late-RT) was amplified with MH531 (5′-GCC TCA ATA AAG CTT GCC TTGA-3′) and MH532 (5′-GCC TCA ATA AAG CTT GCC TTG A-3′) primers and LRT-P probe (5′-FAM-CAG TGG CGC CCG AAC AGG GA-TAMRA-3′). For 2-LTR circle, the LTR-R3 primer (5′-AGG TAG CCT TGT GTG TGG TAG ATC C-3′), the U5-specific primer (5′-AGG TAG CCT TGT GTG TGG TAG ATC C-3′), and the p-HUS-SS1 probe (5′-FAM-TAG TGT GTG CCC GTC TGT TGT GTG AC-TAMRA-3′) were used. The 20-μL reaction mixture contained 2 μL of sample or standard DNA, and the following final concentrations of 1× Premix Ex Taq (probe qPCR) (Takara), 0.2 μM sense primer, 0.2 μM antisense primer, 0.1 μM probe, and 1× ROX Reference Dye II. PCR was performed using an ABI PRISM 7500 Fast Real-Time PCR System (Applied Biosystems). Cycling conditions included a hot start (95 °C for 2 min), 40 cycles of denaturation (95 °C for 15 s), and an extension steps (60 °C for 30 s).
HIV-1 RTase RDDP activity was measured by a DIG-labelled ELISA assay using the Reverse Transcriptase Kit (Roche, Germany), according to manufacturer′s instructions.
HIV-1IIIB recombinant RT (rRTase) expression and purification
HIV-1IIIB RTase p66 and p51 subunits were cloned into two pET-30a vectors, and recombinant p66- and p51-His subunits were over-expressed in E. coli BL21(DE3). The p66/p51-His heterodimer was purified by Ni2+ affinity agarose purification as previously described28. The rRTase was used for the following two assays.
PPT-primed DDDP activity
HIV-1 RTase DDDP activity was measured via fluorescent resonance energy transfer (FRET) assay as previously described, with minor modifications17. The DNA template (5′-AF488-AGT CCC CCC TTT TCT TTT AAA AAG TGG CTA AGA), and the DNA primer (PPT-based) (5′-TTA AAA GAA AAG GGG GG) were synthesized by Sangon Biotech (China). Briefly, DNA template and DNA primer were annealed at temperatures ranging from 90 °C to room temperature to form 20 μM DNA/DNA hybrids. A dXTP mixture of dATP, dCTP, dGTP, and dUTP-AF555 was prepared at 0.4 μM. rRTase was dissolved in reaction buffer (50 mM Tris, 80 mM KCl, 6 mM MgCl2, 0.025% (m/v) CHAPS, 1 mM DTT, and 0.1 mM EGTA pH 7.8) at 320 ng/mL. The 50-μL enzymatic reaction, preceded by incubation for 15 min at room temperature, contained 320 ng/ml rRTase, 80 nM DNA/DNA hybrids, and the test compounds. The reaction was initiated by adding 50 μL of dXTP to a final volume of 100 μL in a black 96-well plate. The plate was then incubated at room temperature in the dark for 15 min. Finally, the plate was measured using a Flex Station 3 reader (Molecular Device, USA) with excitation at 485 nm and emission at 530 nm (cutoff = 515 nm), and the EC50 was calculated.
RNase H activity
HIV-1 RNase H activity was measured by FRET assay as previously described, with minor modifications29. The DNA (DD18) (5′-Dabcyl-AGC TCC CAG GCT CAG ATC) and RNA (FR18) (5′-GAU CUG AGC CUG GGA GCU-fluorescein) fragments were synthesized by Takara (China). Briefly, DD18 and FR18 were annealed at temperatures ranging from 90 °C to room temperature to form 10 μM RNA/DNA hybrids. rRTase was dissolved in reaction buffer (the same as the one used to measure the DDDP activity) at 400 ng/mL. Fifty microliters of a 0.4 μM RNA/DNA hybrid solution was mixed with the compound dilutions to a final concentration of 100 μL in a black 96-well plate. The reaction was initiated by adding 50 μL of rRTase solution and incubated at 37 °C for 1 h. The plate was measured using a Flex Station 3 reader, with excitation at 490 nm and emission at 525 nm (cutoff = 515 nm), and the EC50 was calculated.
Viral plus-strand DNA assay
(i) Infection of C8166 by HIV-1IIIB. In a 6-well plate, 5 × 106 C8166 cells were infected by HIV-1IIIB (M.O.I. = 0.5) with serial dilutions of SJP-L-5 (50 μM, 5 μM, and 0.5 μM,) or NVP (1000 nM, 100 nM, and 10 nM) in a final volume of 8 mL RPMI-1640 media containing 10% FBS and 1 μM RAL. RAL was used to prevent viral DNA integration into host chromosomes. The plate was then incubated in a humidified CO2 incubator at 37 °C for 48 h. (ii) Hirt DNA preparation. The unintegrated viral DNA was extracted following Hirt’s methods30,31. (iii) Southern blot. All DNA samples were digested by Pst I (Fermentas, China). Following denaturation in boiling water, the DNA was immediately cooled in ice/water. DNA was then subjected to electrophoresis in 0.7% agarose gel in 0.5× TBE and analyzed by DIG-labelled chemiluminescent Southern blot according to manufacturer’s instructions (DIG-high prime DNA labeling and detection starter kit II, Roche). The probes used here were a double-stranded HIV-1 DNA fragments within the RTase gene(from the position 2096 to 3375 of HIV-1IIIB genome, GenBank accession number: EU541617), which hybridized to both the minus and the upstream plus strands, or a single-strand DNA fragment within the gp41 gene (from the position 6296 to 6886 of HIV-1IIIB genome), which hybridized to the downstream plus strand5. The chemiluminescent signal was recorded on X-ray film (Kodak, China). The gray value of the film was analyzed via ImageJ 1.46r software.
Selection of SJP-L-5-resistant variant viruses
The viruses resistant to SJP-L-5 were selected by adding the compound progressively to HIV-1IIIB-infected C8166 cells, according to previously described methods32. Briefly, HIV-1IIIB-infected C8166 cells were cultured with 0.9 μM SJP-L-5. Every ~7 days, when syncytia formation was observed to be over 80%, a doubled concentration of SJP-L-5 was added until the compound reached a concentration of 122 μM.
Genotypic resistance assays
SJP-L-5-resistant virus variants were used to analyze the phenotypic and genotypic resistance features of the compound. The RNA of the resistant virus was extracted and reverse transcribed to cDNA. RTase gene of the cDNA was amplified by PCR as previously reported33. A full-length RTase-encoding sequence of 1680 bp was cloned, and positive clones were selected. After sequencing analysis, the gene was aligned with the wild-type HIV-1IIIB strain sequence (GenBank accession number: EU541617). Mutation frequency was then calculated.
Construction of site-directed mutants (SDM) for phenotypic resistance assays
SDM were constructed based on the HIV-1 infectious clone pNL4-3. Mutagenesis was carried out by using the Fast mutagenesis system kit (TransGen, China) according to manufacturer’s instructions. V108I, E138K, and Y181C were introduced into the RTase gene. These mutant plasmids were transfected into C8166 cells using TurboFect (Fermentas, China) according to manufacturer’s instructions. The supernatant of each mutated virus was collected and stored at −70 °C.
Antiviral activity of SJP-L-5 against resistant viruses and site-directed mutants
Nucleoside resistant HIV-1 strains (HIV-1A018 and HIV-174V), non-nucleoside resistant HIV-1 strains (HIV-1A17 and HIV-1), and RTase mutant strains (V108I, E138K, and Y181C) were used. The antiviral activity assay was performed as previously described34.
The results were expressed as the mean ± standard deviation (SD). Statistical significance was determined with Student’s t-test using the SPSS 17.0 software. Differences were significant at P < 0.05.
Das, K. & Arnold, E. HIV-1 reverse transcriptase and antiviral drug resistance. Part 1. Curr. Opin. Virol. 3, 111–118 (2013).
Kupiec, J.-J. & Sonigo, P. Reverse Transcriptase Jumps and Gaps. J. Gen. Virol. 77, 1987–1991 (1996).
Le Grice, S. F. J. Human Immunodeficiency Virus Reverse Transcriptase: 25 Years of Research, Drug Discovery, and Promise. J. Biol. Chem. 287, 40850–40857 (2012).
Charneau, P., Alizon, M. & Clavel, F. A second origin of DNA plus-strand synthesis is required for optimal human immunodeficiency virus replication. J. Virol. 66, 2814–2820 (1992).
Zennou, V. et al. HIV-1 genome nuclear import is mediated by a central DNA flap. Cell 101, 173–185 (2000).
de Bethune, M. P. Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: A review of the last 20 years (1989-2009). Antivir. Res. 85, 75–90 (2010).
Bai, R. et al. SJP-L-5, a novel small-molecule compound, inhibits HIV-1 infection by blocking viral DNA nuclear entry. BMC Microbol. 15, 274 (2015).
Hulme, A. E., Perez, O. & Hope, T. J. Complementary assays reveal a relationship between HIV-1 uncoating and reverse transcription. Proc. Natl. Acad. Sci. USA 108, 9975–9980 (2011).
Charneau, P. & Clavel, F. A single-stranded gap in human immunodeficiency virus unintegrated linear DNA defined by a central copy of the polypurine tract. J. Virol. 65, 2415–2421 (1991).
Hungnes, O., Tjotta, E. & Grinde, B. The Plus Strand Is Discontinuous in a Subpopulation of Unintegrated HIV-1 DNA. Arch. Virol. 116, 133–141 (1991).
Merluzzi, V. J. et al. Inhibition of HIV-1 Replication by a Nonnucleoside Reverse-Transcriptase Inhibitor. Science 250, 1411–1413 (1990).
Dueweke, T. J. et al. U-90152, a potent inhibitor of human immunodeficiency virus type 1 replication. Antimicrob. Agents Chemother. 37, 1127–1131 (1993).
Young, S. D. et al. L-743, 726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 39, 2602–2605 (1995).
Andries, K. et al. TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 48, 4680–4686 (2004).
Azijn, H. et al. TMC278, a Next-Generation Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI), Active against Wild-Type and NNRTI-Resistant HIV-1. Antimicrob. Agents Chemother. 54, 718–727 (2010).
Gilboa, E., Mitra, S. W., Goff, S. & Baltimore, D. Detailed Model of Reverse Transcription and Tests of Crucial Aspects. Cell 18, 93–100 (1979).
Cauchon, E., Falgueyret, J. P., Auger, A. & Melnyk, R. A. A High-Throughput Continuous Assay for Screening and Characterization of Inhibitors of HIV Reverse-Transcriptase DNA Polymerase Activity. J. Biomol. Screen. 16, 518–524 (2011).
Menendez-Arias, L. Molecular basis of human immunodeficiency virus type 1 drug resistance: overview and recent developments. Antivir. Res. 98, 93–120 (2013).
Arts, E. J. & Hazuda, D. J. HIV-1 Antiretroviral Drug Therapy. Cold Spring Harb. Perspect. Med. 2, a007161–a007161 (2012).
Kobayashi, M. et al. In Vitro Antiretroviral Properties of S/GSK1349572, a Next-Generation HIV Integrase Inhibitor. Antimicrob. Agents Chemother. 55, 813–821 (2011).
Velthuisen, E. J. et al. Pyridopyrimidinone inhibitors of HIV-1 RNase H. Euro. J. Med. Chem. 83, 609–616 (2014).
Lansdon, E. B. et al. Structural and Binding Analysis of Pyrimidinol Carboxylic Acid and N-Hydroxy Quinazolinedione HIV-1 RNase H Inhibitors. Antimicrob. Agents Chemother. 55, 2905–2915 (2011).
Arhel, N. J. et al. HIV-1 DNA Flap formation promotes uncoating of the pre-integration complex at the nuclear pore. EMBO J. 26, 3025–3037 (2007).
Menendez-Arias, L., Sebastian-Martin, A. & Alvarez, M. Viral reverse transcriptases. Virus Res. 234, 153–176 (2017).
Vingerhoets, J. et al. TMC125 displays a high genetic barrier to the development of resistance: evidence from in vitro selection experiments. J. Virol. 79, 12773–12782 (2005).
Clutter, D. S., Jordan, M. R., Bertagnolio, S. & Shafer, R. W. HIV-1 drug resistance and resistance testing. Infect., Genet. Evol. 46, 292–307 (2016).
Junghans, R. P., Boone, L. R. & Skalka, A. M. Products of reverse transcription in avian retrovirus analyzed by electron microscopy. J. Virol. 43, 544–554 (1982).
Hou, E. W., Prasad, R., Beard, W. A. & Wilson, S. H. High-level expression and purification of untagged and histidine-tagged HIV-1 reverse transcriptase. Protein Expr. Purif. 34, 75–86 (2004).
Parniak, M. A., Min, K. L., Budihas, S. R., Le Grice, S. F. J. & Beutler, J. A. A fluorescence-based high-throughput screening assay for inhibitors of human immunodeficiency virus-1 reverse transcriptase-associated ribonuclease H activity. Anal. Biochem. 322, 33–39 (2003).
Hirt, B. Selective Extraction of Polyoma DNA from Infected Mouse Cell Cultures. J. Mol. Biol. 26, 365–369 (1967).
Ziegler, K., Bui, T., Frisque, R. J., Grandinetti, A. & Nerurkar, V. R. A rapid in vitro polyomavirus DNA replication assay. J. Virol. Methods. 122, 123–127 (2004).
Zhang, X. J. et al. DB-02, a C-6-cyclohexylmethyl substituted pyrimidinone HIV-1 reverse transcriptase inhibitor with nanomolar activity, displays an improved sensitivity against K103N or Y181C than S-DABOs. PLoS ONE 8, e81489 (2013).
Liu, S. Y., Zhuang, D. M., Dong, R. H., Bai, L. & Li, J. Y. In vitro selection and identification of HIV strain which is resistance to two new HIV-1 nonnucleoside reverse transcriptase inhibitors. Acta Pharm. Sin. 45, 241–246 (2010).
Wang, R. R. et al. Azvudine, a novel nucleoside reverse transcriptase inhibitor showed good drug combination features and better inhibition on drug-resistant strains than lamivudine in vitro. PLoS ONE 9, e105617 (2014).
This work was supported in part by grants from the National Natural Science Foundation of China (81102483, 81001462, 81422046, U1702286 and 21762048), the Key Scientific and Technological Program of China (2013ZX09103001-010 and2014ZX10005-002-006), the Yunnan Applicative and Basic Research Program (2015FB182 and 2015BC002), the CAS Institutes of Materia Medica (CASIMM0320163020), the Collaborative Innovation Center for Natural Products and Biological Drugs of Yunnan, and the Program for Changjiang Scholars and Innovative Research Team in University (IRT_17R94) and the Key Program of Natural Science of Yunnan Province to W.L. Xiao.
The authors declare no competing interests.
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
About this article
Cite this article
Zhang, XJ., Wang, RR., Chen, H. et al. SJP-L-5 inhibits HIV-1 polypurine tract primed plus-strand DNA elongation, indicating viral DNA synthesis initiation at multiple sites under drug pressure. Sci Rep 8, 2574 (2018). https://doi.org/10.1038/s41598-018-20954-5